Fortrea Holdings (FTRE) Other financing activities (2022 - 2023)

Fortrea Holdings (FTRE) posted Other financing activities of -$159.9 million for Q2 2023, down 752.65% on a QoQ basis from $24.5 million in Q1 2023.

Fortrea Holdings (FTRE) Other financing activities (2022 - 2023) Analysis & Trends

Fortrea Holdings' Other financing activities history runs 2 years deep, the most recent figure standing at -$159.9 million for Q2 2023.

Quarterly Other financing activities changed N/A year-over-year to -$159.9 million in Q2 2023, while the trailing twelve-month figure through Mar 2024 was -$159.9 million (changed N/A YoY) and the FY2023 annual result came in at -$135.4 million, down 2049.21% from the prior year.
Other financing activities was -$159.9 million for Q2 2023 at Fortrea Holdings, down from $24.5 million in the prior quarter.
Across five years, Other financing activities topped out at $24.5 million in Q1 2023 and bottomed at -$159.9 million in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Fortrea Holdings	1.83 Bn	1.68 Bn	123.60 Mn

Download Data